CLDX FY 2018 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-25.2% YoY

Gross Profit

-$57M-596.7% margin

Operating Income

-$156M-1640.1% margin

Net Income

-$151M-1585.1% margin

EPS (Diluted)

$-14.48

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$76M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$156M

Total Liabilities

$32M

Stockholders' Equity

$124M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$13M	-25.2%
Gross Profit	-$57M	-$83M	+31.8%
Operating Income	-$156M	-$122M	-28.7%
Net Income	-$151M	-$93M	-62.5%